FDA
-
-
-
-
-
-
-
Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share
-
-
-
-
-
-
-
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
-
-
-
-
-
-
-
Quest Diagnostics (DGX) Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
-
-
-
-
-
-
-
Quest Diagnostics (DGX) Awarded CDC Contracts for H5 Avian Influenza and Oropouche Virus Test Development
-
-
-
-
-
-
-
Quest Diagnostics (DGX) and Universal DX Collaborate to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the US
-
-
-
-
-
-
-
Quest Diagnostics Elects Luis A. Diaz, Jr., M.D. to Its Board, Expanding the Number of Directors to 10
-
-
-
-
-
-
-
Quest Diagnostics Announces Organizational Changes to Accelerate Growth and Drive Operational Excellence
-
329,544 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

